- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.09. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.09. | Sera Prognostics forciert Kommerzialisierung des PreTRM-Tests | 1 | Investing.com Deutsch | ||
| 21.08. | Sera Prognostics übertrifft Gewinnprognose - Aktie steigt trotz schwachem Umsatz | 3 | Investing.com Deutsch | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 07.08. | Sera Prognostics outlines European expansion and new commercial hires while targeting PreTRM Test reimbursement pilots | 1 | Seeking Alpha | ||
| 06.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 44 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 05.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
| 08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | 9 | Investing.com Deutsch | ||
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 170 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 282 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 200 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 144 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,760 | 0,00 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| OCUGEN | 1,018 | +3,59 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 20,180 | +1,01 % | AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play? | ||
| COSCIENS BIOPHARMA | 2,160 | -6,90 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 6,562 | +0,46 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| VAXART | 0,300 | -0,66 % | Vaxart, Inc.: Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate | - Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study - SOUTH SAN... ► Artikel lesen | |
| IBIO | 0,725 | -0,68 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,520 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights | Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts
Commercial and R&D Highlights:
... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,760 | +1,46 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| CARDIFF ONCOLOGY | 1,668 | -1,30 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| ALDEYRA | 4,155 | -0,57 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MANNKIND | 4,450 | -1,83 % | MannKind auf Morgan-Stanley-Konferenz: Strategische Diversifikation und Expansion in neue Therapiegebiete | ||
| TRAWS PHARMA | 2,020 | 0,00 % | Traws Pharma, Inc. - 8-K, Current Report | ||
| COHERUS ONCOLOGY | 1,157 | +1,23 % | Strategiewechsel bei Coherus: Voller Fokus auf Immunonkologie |
SERA PROGNOSTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.